Pharmaceuticals discovered with AI
EFFICIENT DRUG DISCOVERY & DEVELOPMENT
twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.
twoXAR Pharmaceuticals
Drug Discovery and Development Overview
May 2020
LATEST NEWS
LATEST EVENTS
EPPIC Global Presents: Role of AI/ML in transforming and accelerating the drug discovery process
EPPIC Global (Digital)
October 17, 2020
twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.
MIT ILP: Precision Medicine in Oncology
MIT ILP (Digital)
October 16, 2020
twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules for oncology and more using AI.
Level Up: Leveraging AI for Drug Discovery as a Biology Startup
Johnson & Johnson Innovaion | JLabs Panel (Digital)
October 1, 2020
twoXAR Pharmaceuticals CEO Andrew A. Radin presents and joins the JLabs Panel to discuss how biology startups can partner with AI companies.
© 2020 twoXAR, Incorporated | All Rights Reserved